Document Detail

Cancer screening of long-term cancer survivors.
MedLine Citation:
PMID:  22773714     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Although 64% of cancer survivors are expected to live at least 5 years beyond diagnosis, the receipt of cancer screening by this population is unclear. The objective of this study was to assess the relation between a cancer diagnosis and future cancer screening, exploring provider-, patient-, and cancer-specific factors that explain observed relationships.
METHODS: The Wisconsin Longitudinal Study (WLS) and Wisconsin Tumor Registry were used to identify 2 participant groups: 415 patients diagnosed with nonmetastatic cancer between 1992 to 1993 (before cancer) and 2003 to 2004 (after cancer) and 4680 controls (no cancer). Adjusted average predicted probabilities of cancer screening were estimated with models that first did not include and then included, provider (provider relationship length), participant (depressive symptoms per the Center for Epidemiologic Studies Depression Scale), and cancer-specific (time since diagnosis) factors. Participants with a history of cancer associated with a given screening test were then excluded to assess whether relationships are explained by screening for recurrence versus second cancers.
RESULTS: Female cancer survivors were more likely than no-cancer controls to undergo pelvic/Papanicolaou screening (survivors: 70%, 95% confidence interval [CI]: 63% to 76%; controls: 61%, 95% CI: 59% to 63%) and mammography screening (survivors: 86%, 95% CI: 78% to 90%; controls: 76%, 95% CI: 74% to 77%), though male cancer survivors were not more likely to receive prostate exams (survivors: 76%, 95% CI: 70% to 82%; controls: 69%, 95% CI: 67% to 71%). After excluding people with a history of the cancer being screened for, there were few significant differences in cancer screening between short- or long-term survivors (≥5 years) and no-cancer controls. Relationships were not sensitive to adjustment for provider or participant factors.
CONCLUSIONS: The significant positive differences in cancer screening between people with and without cancer can be explained by screening for recurrence. Long-term cancer survivors are not more likely to receive follow-up screening for second cancers. This information should be used by providers to ensure patients receive recommended follow-up preventive care.
Jessica R Schumacher; Whitney P Witt; Mari Palta; Noelle K Loconte; Susan M Heidrich; Amy Trentham-Dietz; Nancy Pandhi; Maureen A Smith
Related Documents :
24832944 - Mortality and cancer incidence in ammonium perfluorooctanoate production workers.
23496874 - Hashimoto's thyroiditis, microcalcification and raised thyrotropin levels within normal...
24946744 - Use of oral anticoagulants and risk of prostate cancer: a population-based case-control...
23057394 - Oral and pharyngeal cancers in yemen: a retrospective study.
23475354 - A single-molecule force spectroscopy study of the interactions between lectins and carb...
8684294 - Recent data on cancer due to asbestos in germany.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the American Board of Family Medicine : JABFM     Volume:  25     ISSN:  1557-2625     ISO Abbreviation:  J Am Board Fam Med     Publication Date:    2012 Jul-Aug
Date Detail:
Created Date:  2012-07-09     Completed Date:  2012-11-30     Revised Date:  2014-09-24    
Medline Journal Info:
Nlm Unique ID:  101256526     Medline TA:  J Am Board Fam Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  460-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Longitudinal Studies
Mass Screening / utilization*
Middle Aged
Neoplasms / diagnosis*
Grant Support
HS000083/HS/AHRQ HHS; HS000083-12/HS/AHRQ HHS; K08 AG029527/AG/NIA NIH HHS; K08 AG029527-05/AG/NIA NIH HHS; K12 HD055894/HD/NICHD NIH HHS; L K08 AG029527/AG/NIA NIH HHS; P01 AG021079/AG/NIA NIH HHS; P01 AG021079/AG/NIA NIH HHS; P01 AG021079-08/AG/NIA NIH HHS; P30 CA014520/CA/NCI NIH HHS; R01 AG009775/AG/NIA NIH HHS; R01 AG009775-16/AG/NIA NIH HHS; R01 AG033285/AG/NIA NIH HHS; R01 AG033285/AG/NIA NIH HHS; R01 AG033285-03/AG/NIA NIH HHS; R01 AG09775/AG/NIA NIH HHS; R21 CA137288/CA/NCI NIH HHS; R21 CA137288/CA/NCI NIH HHS; R21 CA137288-02/CA/NCI NIH HHS; UL1 RR025011/RR/NCRR NIH HHS; UL1 RR025011/RR/NCRR NIH HHS; UL1 RR025011-05/RR/NCRR NIH HHS; UL1 TR000064/TR/NCATS NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Azithromycin for bronchial asthma in adults: an effectiveness trial.
Next Document:  Satisfaction of family physicians working in community health centers.